Significant Corporate Announcements: Guanghe Technology (01989) initiated its public offering from March 12 to March 17, planning a global sale of 46 million H shares. Sino Biopharmaceutical (01177) announced that the clinical trial for TQB3205 (a pan-KRAS inhibitor) has received approval from the NMPA. Binhai Investment (02886) entered into a strategic cooperation framework agreement with TEDA Urban Renewal to jointly promote the national "Good Houses" initiative and enhance urban quality. Hengrui Pharmaceuticals (01276) disclosed that its SHR-2524 injection has obtained a drug clinical trial approval notice. Lepu Biopharma-B (02157) reported that AstraZeneca has paid a milestone payment of $45 million.

Operational Performance: LAOPU GOLD (06181) issued a positive profit alert, forecasting a net profit attributable for the 2025 fiscal year in the range of approximately 4.8 billion to 4.9 billion yuan, representing a year-on-year increase of about 226% to 233%. Cathay Pacific Airways (00293) released its full-year 2025 results, reporting a profit attributable to shareholders of HK$10.828 billion, up 9.51% year-on-year. Metallurgical Corporation of China (01618) reported new contract signings valued at 132.44 billion yuan for the first two months of the year, a decrease of 6.49% compared to the same period last year. Far East Horizon (03360) announced its 2025 annual results, with profit attributable to owners for the year reaching 3.889 billion yuan, a slight increase of 0.67%. Yue Yuen Industrial (00551) disclosed its 2025 financial results, showing a profit attributable to owners of the company of approximately $381 million, a decrease of 2.9% compared to the previous year.